No annual revenue total was found in Parabilis Medicines, Inc.'s SEC filings.
Parabilis Medicines, Inc. (PBLS) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $1.1 billion in cash and investments and $53.2 million in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$1.07B
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1657677
- Former names
- FOG PHARMACEUTICALS, INC. (until Dec 2, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 25, 2026 | Aug 22, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
Jun 11, 2026 | Jun 9, 2026 |
All 62 Parabilis Medicines, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.